Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- LPA-3 ICC WB antibodies Edg7 GPCR S1P Hep-G2 HepG-2
- Product Overview:
Lysophosphatidic acid receptor 3 (LPA3, also known as EDG-7) is one of three LPA receptors (LPA1, LPA2, and LPA3) that are members of large family of G protein-coupled receptors that also include those for sphingosine-1-phosphate (S1P1-5).{11049} The LPA receptors mediate many cellular responses including cytoskeletal rearrangements, cell proliferation, and inhibition of gap junction communication.{11808,11809} Mouse and human LPA3 have 353 amino acids with an estimated molecular weight of 40 kDa.{11811,11810} The mRNA level of LPA3 is high in testes, kidney, and lung but low in intestine, heart, thymus, and stomach.{11810} Cayman Chemical’s LPA3 polyclonal antibody can be used for western blot, immunofluorescence, and immunocytochemical analysis for LPA3 on samples of human, mouse, and rat origin. Cayman’s LPA3 Polyclonal Antibody detects a protein at around 40 kDa in human HepG2 cells, mouse macrophages, and in mouse and rat liver.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.